Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to test the safety, tolerable side effects, and determine
the highest tolerable dose of the combination of Regorafenib and Nivolumab. Researchers want
to find out if this combination of Regorafenib and Nivolumab can help people with metastatic
colorectal cancer with mismatch repair (MMR) proficiency.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute